Control of Refractory Hypercalcemia with Denosumab in a Case of Metastatic Parathyroid Carcinoma

Murat Çalapkulu¹, Ozen Oz Gül², Soner Cander², Canan Ersoy², Erdinc Erturk², Muhammed Fatih Sagiroglu³ and Ozlem Saraydaroglu⁴

¹Department of Endocrinology and Metabolism, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey
²Department of Endocrinology and Metabolism, Uludag University Medical School, Turkey
³Department of Internal Medicine, Uludag University Medical School, Turkey
⁴Department of Pathology, Uludag University Medical School, Turkey

ABSTRACT
Parathyroid carcinoma is a rare cause of hyperparathyroidism and leads to severe hypercalcemia. The etiology is not fully known. Parathyroid cancer should be considered in the differential diagnosis, if serum calcium and parathyroid hormone levels increase, and palpable parathyroid gland is detected. Morbidity and mortality in parathyroid carcinoma cases are related to hypercalcemia due to parathormone (PTH) secreted by tumor cells rather than tumor size. The definitive treatment of the disease is surgery. In parathyroid carcinoma patients, the cause of death is usually uncontrolled hypercalcemia. However, life-threatening hypercalcemia can be controlled with fluid replacement, diuretic therapy, bisphosphonates, and calcimimetic agents. Denosumab is a monoclonal antibody that binds to RANKL with a high affinity, disrupts RANKL-RANK interaction, and inhibits bone resorption. Denosumab is generally used in the treatment of post-menopausal osteoporosis and prevention of skeletal-related events in malignancies with bone metastases. Published studies of denosumab treatment in refractory and recurrent hypercalcemia, associated with parathyroid carcinoma, are limited to case reports. In the current case, we report a patient who presented with the complaint of leg pain, was determined to have multiple bone lesions, and was diagnosed with parathyroid carcinoma. The elevated calcium level of the patient was controlled with denosumab.

Key Words: Parathyroid carcinoma, Denosumab, Hypercalcemia, Hyperparathyroidism.


INTRODUCTION
Parathyroid carcinoma is a rare tumor and constitutes 0.5-5% of primary hyperparathyroidism cases. Parathyroid cancer should be considered in the differential diagnosis, if serum calcium and parathyroid hormone levels increase, and palpable parathyroid gland is detected. Morbidity and mortality in parathyroid carcinoma cases are related to hypercalcemia due to parathormone (PTH) secreted by tumor cells rather than tumor size. The definitive treatment of the disease is surgery. In parathyroid carcinoma patients, the cause of death is usually uncontrolled hypercalcemia. However, life-threatening hypercalcemia can be controlled with fluid replacement, diuretic therapy, bisphosphonates, and calcimimetic agents.

Correspondence to: Murat Çalapkulu, Department of Endocrinology and Metabolism, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Sehit Omer Halisdemir Avenue, 06110, Ankara, Turkey
E-mail: calapkulumurat89@gmail.com

Received: July 20, 2019; Revised: July 20, 2019; Accepted: July 21, 2019
DOI: https://doi.org/10.29271/jcpsp.2020.07.757

Denosumab is a monoclonal antibody that binds to RANKL with a high affinity, disrupts RANKL-RANK interaction, and inhibits bone resorption. Denosumab is generally used in the treatment of post-menopausal osteoporosis and prevention of skeletal-related events in malignancies with bone metastases. Published studies of denosumab treatment in refractory and recurrent hypercalcemia, associated with parathyroid carcinoma, are limited to case reports. In the current case, we report a patient who presented with the complaint of leg pain, was determined to have multiple bone lesions, and was diagnosed with parathyroid carcinoma. The elevated calcium level of the patient was controlled with denosumab.

CASE REPORT
A 61-year male patient presented to our clinic with the complaint of widespread leg pain. No pathological findings were found in the physical examination. The laboratory test results revealed serum PTH of 2233 ng/L (Normal: 15-68.3), calcium 15.7 mg/dl (Normal: 8.4-10.2), vitamin D 9.7 μg/L (Normal: 25-100), alkaline phosphatase (ALP) 532 IU/ml (Normal: 40-150), phosphorus 2.9 mg/dl (Normal: 2.3-4), and creatinine 1.99 mg/dl (Normal: 0.7-1.1). Multiple lytic lesions in the pelvis, cranium, and long-bones were observed on radiography. Neck ultrasonography showed a hypoechoic solid nodule with cystic areas, 2x2 cm in size, in the left thyroid gland inferior region; and delayed washout was detected on parathyroid scintigraphy. Metastasis was suspected on bone scintigraphy.
Table I: Serum calcium, parathyroid hormone, phosphorus, and creatinine levels after subcutaneous denosumab therapy. Albumin-corrected serum calcium concentrations in mg/dl in our patient are depicted.

<table>
<thead>
<tr>
<th>A.T. Interval</th>
<th>Serum calcium</th>
<th>Serum phosphorus</th>
<th>Serum parathormoe</th>
<th>Serum creatinine</th>
</tr>
</thead>
<tbody>
<tr>
<td>B.T</td>
<td>12.4 mg/dl</td>
<td>1.8 mg/dl</td>
<td>1549 ng/L</td>
<td>1.41 mg/dl</td>
</tr>
<tr>
<td>First month</td>
<td>11 mg/dl</td>
<td>1.7 mg/dl</td>
<td>2682 ng/L</td>
<td>1.47 mg/dl</td>
</tr>
<tr>
<td>Third month</td>
<td>10.7 mg/dl</td>
<td>1.7 mg/dl</td>
<td>2714 ng/L</td>
<td>1.47 mg/dl</td>
</tr>
<tr>
<td>Sixth month</td>
<td>10.7 mg/dl</td>
<td>1.8 mg/dl</td>
<td>3773 ng/L</td>
<td>1.37 mg/dl</td>
</tr>
</tbody>
</table>

A.T: After treatment, B.T: Before treatment (Reference range: Serum calcium 8.4-10.2 mg/dl, serum phosphorus 2.3-4 mg/dl, serum parathormone 15-68.3 Serum creatin:0.7-1.1 mg/dl)

Figure 1: Sagittal MRI of spine metastases.

Denosumab is a monoclonal antibody, which has been shown to increase bone mineral density in postmenopausal women, to inhibit bone resorption and decrease hypercalcemia in hematological malignancies, and solid tumors with bone metastasis.\(^1\)\(^-\)\(^3\) There is no clinical study in literature that has evaluated the efficacy of denosumab in reducing calcium levels in patients with severe PTH excess due to parathyroid carcinoma. In some case reports about parathyroid carcinoma, denosumab monotherapy has been reported to control refractory hypercalcemia in patients who could not be controlled with surgery, bisphosphonate, calcimimetic, and dacarbazine treatments.\(^5\)\(^,\)\(^6\) Vellanki et al. used bisphosphonate, calcium receptor agonist, and chemotherapy (dacarbazine) treatments for a 39-year patient with metastatic parathyroid carcinoma. However, the serum calcium level could not be brought under control. With the addition of denosumab (120 mg once a month) to the treatment, the calcium level was successfully controlled for 16 months.\(^5\) In another case report by Tong et al., hypercalcemia, induced by metastatic parathyroid cancer, was resistant to standard treatment. Temporary hemodialysis was performed to control hypercalcemia, and subcutaneous calcitonin was also administered several times, but the calcium levels could not be controlled. Oral cinacalcet was initiated, but was not sufficient to control the calcium level. Subcutaneous denosumab of 120 mg/month was administered, and calcium levels rapidly normalised by the third day.\(^6\) In the current case, metastasis was detected in the lung at 19 months postoperatively and the calcium level was not brought under control with bisphosphonate and cinacalcet treatment. Therefore, denosumab was added despite a dose of 90 mg/day. The patient could not tolerate higher doses of cinacalcet because of side-effects. Therefore, denosumab therapy was added as a monthly administration of 120 mg subcutaneously, while continuing a daily cinacalcet dose of 90 mg. After 6 months of denosumab treatment, the calcium levels decreased dramatically (Table I). Biochemical follow-up at 6-12 week interval and follow-up for distant metastases at 3-6 month interval was planned.

**DISCUSSION**

Denosumab is a monoclonal antibody, which has been shown to increase bone mineral density in postmenopausal women, to inhibit bone resorption and decrease hypercalcemia in hematological malignancies, and solid tumors with bone metastasis.\(^1\)\(^-\)\(^3\) There is no clinical study in literature that has evaluated the efficacy of denosumab in reducing calcium levels in patients with severe PTH excess due to parathyroid carcinoma. In some case reports about parathyroid carcinoma, denosumab monotherapy has been reported to control refractory hypercalcemia in patients who could not be controlled with surgery, bisphosphonate, calcimimetic, and dacarbazine treatments.\(^5\)\(^,\)\(^6\) Vellanki et al. used bisphosphonate, calcium receptor agonist, and chemotherapy (dacarbazine) treatments for a 39-year patient with metastatic parathyroid carcinoma. However, the serum calcium level could not be brought under control. With the addition of denosumab (120 mg once a month) to the treatment, the calcium level was successfully controlled for 16 months.\(^5\) In another case report by Tong et al., hypercalcemia, induced by metastatic parathyroid cancer, was resistant to standard treatment. Temporary hemodialysis was performed to control hypercalcemia, and subcutaneous calcitonin was also administered several times, but the calcium levels could not be controlled. Oral cinacalcet was initiated, but was not sufficient to control the calcium level. Subcutaneous denosumab of 120 mg/month was administered, and calcium levels rapidly normalised by the third day.\(^6\) In the current case, metastasis was detected in the lung at 19 months postoperatively and the calcium level was not brought under control with bisphosphonate and cinacalcet treatment. Therefore, denosumab was added...
to the patient’s treatment, and the calcium levels were brought under control.

In conclusion, considering that parathyroid cancer-mediated hypercalcemia is a result of elevated PTH levels, a denosumab-induced decrease in calcium levels suggests that denosumab may prevent the hypercalcemic effect of PTH, and may also have a potential role in the palliative treatment of metastatic parathyroid cancer.

PATIENT’S CONSENT:
Participant were informed about the research protocol and he declared his voluntary attendance with assigned written assent.

CONFLICT OF INTEREST:
The authors declared no conflict of interest.

AUTHORS’ CONTRIBUTION:
MC: Wrote the manuscript.
MC, OOG, SC: Participated in data collection.
MC, OS, MFS: Participated in figure collection.
MC, OOG, CE, EE: Contributed to the Discussion.
MC, OOG, CE, SC, EE: Contributed to study design, reviewed and edited the manuscript.

REFERENCES

• • • • • • •